Literature DB >> 10527678

Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models.

D A Brooks1.   

Abstract

The lysosomal storage disorders (LSD) are a group of severe multiple pathology disorders characterized by enzyme deficiencies which cause the lysosomal accumulation of undegraded or partially degraded macromolecules. Enzyme replacement therapy (ERT) has been developed as a therapy for LSD patients. However, immune responses to ERT have been reported in some individuals from LSD animal model and LSD human patient studies. Antibodies can have adverse effects during ERT, which include hypersensitivity/anaphylactic reactions, enzyme inactivation, altered targeting, and increased enzyme turnover. The monitoring of antibody production during replacement therapy is an important consideration for patient management, as high-titer antibodies can affect the safety and efficacy of the therapy. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10527678     DOI: 10.1006/mgme.1999.2894

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  21 in total

1.  Hematopoietic stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler's syndrome after pharmacological enzyme replacement therapy.

Authors:  Muhammad Ameer Saif; Brian W Bigger; Karen E Brookes; Jean Mercer; Karen L Tylee; Heather J Church; Denise K Bonney; Simon Jones; J Ed Wraith; Robert F Wynn
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

2.  Atypical immunologic response in a patient with CRIM-negative Pompe disease.

Authors:  Mary-Alice Abbott; Sean N Prater; Suhrad G Banugaria; Susan M Richards; Sarah P Young; Amy S Rosenberg; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-08-11       Impact factor: 4.797

3.  Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.

Authors:  Akira Yamaguchi; Kayoko Katsuyama; Kyoko Suzuki; Kenji Kosaka; Ichiro Aoki; Shoji Yamanaka
Journal:  J Mol Med (Berl)       Date:  2003-02-12       Impact factor: 4.599

4.  Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.

Authors:  Angela C Sosa; Barbara Kariuki; Qi Gan; Alan P Knutsen; Clifford J Bellone; Miguel A Guzmán; Luis A Barrera; Shunji Tomatsu; Anil K Chauhan; Eric Armbrecht; Adriana M Montaño
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 5.  A podocyte view of membranous nephropathy: from Heymann nephritis to the childhood human disease.

Authors:  Pierre Ronco; Hanna Debiec
Journal:  Pflugers Arch       Date:  2017-06-08       Impact factor: 3.657

Review 6.  Immunopathogenesis of membranous nephropathy: an update.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  Semin Immunopathol       Date:  2014-04-09       Impact factor: 9.623

7.  Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII.

Authors:  Carole Vogler; Beth Levy; Jeffrey H Grubb; Nancy Galvin; Yun Tan; Emil Kakkis; Nadine Pavloff; William S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-14       Impact factor: 11.205

8.  Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.

Authors:  Nina Raben; Kanneboyina Nagaraju; Alicia Lee; Nina Lu; Yesenia Rivera; Tejas Jatkar; John J Hopwood; Paul H Plotz
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

9.  Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.

Authors:  Li Xue; Adrienne Clements-Egan; Lakshmi Amaravadi; Mary Birchler; Boris Gorovits; Meina Liang; Heather Myler; Shobha Purushothama; Marta Starcevic Manning; Crystal Sung
Journal:  AAPS J       Date:  2017-11-06       Impact factor: 4.009

10.  Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy.

Authors:  Ulrich Matzner; Frank Matthes; Eva Herbst; Renate Lüllmann-Rauch; Zsuzsanna Callaerts-Vegh; Rudi D'Hooge; Cecilia Weigelt; Carl Eistrup; Jens Fogh; Volkmar Gieselmann
Journal:  Mol Med       Date:  2007 Sep-Oct       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.